Last reviewed · How we verify
NCT02971527
Efficacy and Safety Study of Ultrasound Bone Strength Device to Measure Calcaneal Bone Strength Index of Human Subjects
NA trial testing Oste-scan 500A in Clinical Trial in 150 participants. Completed in 9 March 2017.
9 March 2017
Quick facts
| Lead sponsor | The Second Hospital of Nanjing Medical University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 150 |
| Start date | 28 February 2017 |
| Primary completion | 9 March 2017 |
| Estimated completion | 9 March 2017 |
| Sites | 1 location across China |
Drugs / interventions tested
- Oste-scan 500A
- SONOST3000
Conditions studied
- Clinical Trial — all drugs for Clinical Trial →
- Comparative Effectiveness Research — all drugs for Comparative Effectiveness Research →
- Equipment Safety — all drugs for Equipment Safety →
Sponsor
The Second Hospital of Nanjing Medical University
Who can join
Adults 20 to 80, any sex, with Clinical Trial or Comparative Effectiveness Research. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to examine whether ultrasound bone strength device (Model Number: Oste-scan 500A) is effective and safe in measuring calcaneal bone strength index of human subjects, compared with a listed, similar device (Model Number: SONOST3000).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02971527
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Clinical Trial
Currently open trials in the same condition.
- NCT06562387 — tDCS as Adjunctive Therapy to Cognitive Stimulation in Medical Students With Depression · NA · active not recruiting
- NCT04691700 — GOREISAN for Heart Failure (GOREISAN-HF) Trial · Phase 4 · active not recruiting
Other The Second Hospital of Nanjing Medical University trials
Trials by the same sponsor.
- NCT07331688 — CMTS0515-auWMT for Radiation Enteritis · Phase 1, PHASE2 · active not recruiting
- NCT06839586 — CMTS4520 for Chronic Diarrhoea in Adults · Phase 1, PHASE2 · active not recruiting
- NCT06839599 — CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Diarrhoea in Adults · Phase 1, PHASE2 · not yet recruiting
- NCT06844708 — CMTS0929 for Inflammatory Bowel Disease · EARLY_PHASE1 · not yet recruiting
- NCT06836427 — CMTS0929 for Clostridioides Difficile Infection · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02971527 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Second Hospital of Nanjing Medical University
- Last refreshed: 13 April 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02971527.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing